Company Overview
Snapshot
Founded in May 2019, Fibplant operates with 1–10 employees, including founder Haim Eliyahu. The company has secured funding across two rounds, with one disclosed grant event in May 2019.
Business overview
Fibplant is a Health Tech & Life Sciences company focused on developing a genetically engineered fibrinogen. This advanced active composition, based on therapeutic proteins produced in transgenic plants, is designed for use as a biological glue within the existing pharmaceutical drug market. The company's core technology serves the surgery and emergency medicine sectors, operating within the broader biopharmaceutical and drug development industries, with a focus on North America, Europe, and Southeast Asia.
Log in to access full profile ›Company Intelligence Q&A
- What is Fibplant's core technology?
- Fibplant is developing a genetically engineered fibrinogen, which is an advanced active composition based on therapeutic proteins produced in transgenic plants. This technology is designed for use as a biological glue in medical applications.
- When was Fibplant founded?
- Fibplant was founded in May 2019.
- Which markets does Fibplant target?
- Fibplant targets the North America, Europe, and Southeast Asia markets with its genetically engineered fibrin sealant technology.
- What is the primary application of Fibplant's product?
- Fibplant's genetically engineered fibrinogen is intended to be used as a biological glue for existing pharmaceutical drug markets, specifically within surgery and emergency medicine.
- What was a key early funding event for Fibplant?
- In May 2019, Fibplant secured a grant, contributing to its early-stage development.